/PRNewswire/ - The combination of ibrutinib and venetoclax may be effective for treating patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Share this article
Share this article
TORONTO, June 11, 2021 /CNW/ - Switch Health today announced the introduction of AuraPass, its groundbreaking digital vaccine and COVID-19 test verification technology that paves the way as the next reliable solution in keeping Canadians safe, as the country begins reopening for business.
Switch Health introduces AuraPass as the next step to safely reopen Canada s economy (CNW Group/Switch Health Inc.)
AuraPass is a privacy-first, three-step medical record and results-sharing solution, that will verify a patient s government-issued ID, vaccination status, or recent COVID-19 test result, to help facilitate Canada s reopening. AuraPass holds historical vaccination and COVID-19 result data for registered patients through its encrypted blockchain technology that allows the user to securely share required status with venues, airlines and workplaces as they choose. The technology s cutting-edge standards and framework are aligned with those due to
/PRNewswire/ The Pfizer/BioNTech BNT162b2 vaccine has been approved for the prevention of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
/CNW/ - While we continue to see high levels of COVID-19 vaccine uptake across the country, access is not always equitable and some communities benefit from.